NEW YORK (GenomeWeb News) – Saladax Biomedical today said that it will offer its My5-FU assay as part of its MyCare service offering later this year after regaining marketing rights to the test from Myriad Genetics.

The Bethlehem, Pa.-based firm said that it would begin offering the assay, which is used to help guide optimized dosing of infusional 5-fluorouracil to patients, later this year when its CLIA lab commences operations in June. 5-FU is used to treat several types of cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.